Amoeba

Overview
Price performance
Financials
Research
Thematics

Amoéba is a greentech based in France, which aims to become a major player in treating microbiological risk in the crop protection and cosmetic sectors. Based on the natural properties of a unique, exclusively patented microorganism, its biological solutions offer a viable alternative to the chemical products widely used in the industry today.

P&S Intelligence’s report noted that the global biocontrol agents market was worth c $4.9bn in 2021 and predicted it would increase to $13.6bn by 2030. According to McKinsey, the global skincare market was $200bn in 2022 and is expected to expand at a CAGR of 6% from 2022 to 2027. There are clear trends towards natural ingredients and premium products, with McKinsey forecasting that the premium end of the market should grow at an 8% CAGR, compared with 5% for the mass market and 6% for the global market. This trend should represent a significant tailwind to any Amoéba product sourced from a natural spring in the south of France.

Latest Insights

Industrials |
Outlook

21.06.24

Amoeba — Focused on high-value opportunities

Industrials |
Update

16.11.23

Amoeba — Biocontrol plant paves path to commercialisation

Industrials |
Update

22.05.23

Amoeba — Scaling up for commercialisation

Industrials |
Update

03.04.23

Amoeba — Building on an exceptional year

Visit Website

Sector

Industrials

Equity Analyst

Michael McNamara

Key Management

Benoit Villers

Chairman
Jean-Francois Doucet

CEO

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	49.4	46.4	96.3
Relative	57.9	51.9	97.7
52 week high/low	€0.8/€0.4

Financials

FY23 grant income was €0.2m higher year-on-year, which was more than offset by a surge in operating costs of €1m to €7.3m, resulting in a widening of the EBIT loss by €0.8m to €6.6m. At end-FY23, Amoéba had €0.5m cash (€5.5m at end-FY22) on its balance sheet and €4.9m debt (€2.4m at end-FY22). The company is fully funded through CY24 via an existing debt facility with its lead shareholder. Amoéba expects to generate first revenues in 2026 and can meet early demand from existing production capacity.